Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q2 2020 · 10-Q
Revenue$473.00K$473.00K−93.6% vs Q2 2019 Net Income-$6.80M-$6.80MN/M vs Q2 2019 EPS Diluted-$2.10-$2.10N/M vs Q2 2019 Operating Income-$6,807,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-1439.1%−1263.9 pt vs Q2 2019
Net margin-1438.3%−1257.1 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end